Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection

Antiviral Therapy

Volumn 14, Issue 5, 2009, Pages 641-647

  BenMarzouk Hidalgo, Omar Jesus ^a   Cordero, Elisa ^a   Martin Peña, Almudena ^a   Garcia Prado, Elena ^a   Gentil, Miguel Angel ^a   Gomez Bravo, Miguel Angel ^a   Bárrera Pulido, Lydia ^a   Cisneros, Jose Miguel ^a   Perez Romero, Pilar ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN PP65; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD; VIRUS REPLICATION;

EID: 69849087409     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Sissons JG, Carmichael AJ. Clinical aspects and management of cytomegalovirus infection. J Infect 2002; 44:78-83.
2. Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 2008; 14:4849-4860.
3. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355:2032-2036.
4. Villacian JS, Paya CV. Prevention of infections in solid organ transplant recipients. Transpl Infect Dis 1999; 1:50-64.
5. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34:1094-1097.
6. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338:1741-1751.
7. Perez-Sola MJ, Caston JJ, Solana R, Rivero A, Torre-Cisneros J. Indirect effects of cytomegalovirus infection in solid organ transplant recipients. Enferm Infecc Microbiol Clin 2008; 26:38-47.
8. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601-2614.
9. Miller GG, Kaplan B. Prophylaxis versus preemptive protocols for CMV: do they impact graft survival? Am J Transplant 2008; 8:913-914.
10. Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996; 2:537-549.
11. Fishman A, Emery V, Freeman R, et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007; 21:149-159.
12. Jung C, Engelmann E, Borner K, Offermann G. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Transplant Proc 2001; 33:3621-3623.
13. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6:2134-2143.
14. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preeimptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8:69-77.
15. Palmer SM, Grinnan DC, Reams BD, Steele MP, Messier RH, Davis RD. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Clin Transplant 2004; 18:179-185.
16. Singh N. Optimal prevention of late-onset cytomegalovirus (CMV) disease and other sequelae of CMV infection in organ transplant recipients. Clin Infect Dis 2008; 47:296-297.
17. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 2000; 97:8039-8044.
18. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22:162-170.
19. Boivin G, Goyette N, Gilbert C, Covington E. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol 2005; 77:425-429.
20. Lilleri D, Baldanti F, Gatti M, et al. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infectious in solid organ and hematopoietic stem cell transplant recipients. J Med Virol 2004; 73:412-418.
21. Martin-Davila P, Fortun J, Gutierrez C, et al. Analysis of quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the cut-off value. J Clin Virol 2005; 33:138-144.
22. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001; 32:742-751.
23. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998; 11:533-554.
24. van der Bij W, Schirm J, Torensma R, van Son WJ, Tegzess AM, The TH. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 1988; 26:2531-2535.
25. Schirm J, Timmerije W, van der Bij W, et al. Rapid detection of infectious cytomegalovirus in with the aid of monoclonal antibodies. J Med Virol 1987; 23:31-40.
26. Land ML, Ferguson D, Cohen S, Huber K, Wetherill P. Effect of delayed specimen processing on cytomegalovirus antigenemia test results. J Clin Microbiol 1995; 33:257-259.
27. Deback C, Fillet AM, Dhedin N, et al. Monitoring of human cytomegalovirus infection in immunosuppressed patients using real-time PCR on whole blood. J Clin Virol 2007; 40:173-179.
28. Mengelle C, Pasquier C, Rostaing L, et al. Quantitation of human cytomegalovirus in recipients of solid organ transplants by real-time quantitative PCR and pp65 antigenemia. J Med Virol 2003; 69:225-231.
29. Kim DJ, Kim SJ, Park J, et al. Real-time PCR assay compared with antigenemia assay for detecting cytomegalovirus infection in kidney transplant recipients. Transplant Proc 2007; 39:1458-1460.
30. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol 20061; 16:281-287.
31. Snydman DR. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol 2006; 16:289-295.
32. Abbate I, Finnstrom N, Zaniratti S, et al. Evaluation of an automated extraction system in combination with Affigene CMV Trender for CMV DNA quantitative determination: comparison with nested PCR and pp65 antigen test. J Virol Methods 2008; 151:61-65.
33. Bernabeu-Wittel M, Pachon-Ibanez J, Cisneros JM, et al. Quantitative pp65 antigenemia in the diagnosis of cytomegalovirus disease: prospective assessment in a cohort of solid organ transplant recipients. J Infect 2005; 51:188-194.
34. Cariani E, Pollara CP, Valloncini B, Perandin E, Bonfanti C, Manca N. Relationship between pp65 antigenemia levels and real-time quantitative DNA PCR for human cytomegalovirus (HCMV) management in immunocompromised patients. BMC Infect Dis 2007; 7:138.
35. Pescovitz MD. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 2006; 82 Suppl 2:S4-S8.